Bank of America Corp DE Has $1.47 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

Bank of America Corp DE reduced its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 36.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 54,185 shares of the company's stock after selling 31,021 shares during the quarter. Bank of America Corp DE owned approximately 0.09% of Structure Therapeutics worth $1,469,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. ANTIPODES PARTNERS Ltd increased its stake in shares of Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares during the last quarter. Virtus ETF Advisers LLC boosted its holdings in Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after purchasing an additional 455 shares during the period. Assetmark Inc. grew its position in Structure Therapeutics by 72.3% in the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after purchasing an additional 953 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Structure Therapeutics by 673.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock worth $111,000 after purchasing an additional 3,549 shares during the period. Finally, Headlands Technologies LLC bought a new position in shares of Structure Therapeutics during the 4th quarter worth about $113,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on GPCR. HC Wainwright reduced their target price on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Monday, May 12th. William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, Citigroup started coverage on Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $79.86.

Structure Therapeutics Stock Down 1.6%

Shares of Structure Therapeutics stock traded down $0.34 during trading on Friday, reaching $21.13. The company's stock had a trading volume of 1,227,831 shares, compared to its average volume of 881,379. The firm has a market cap of $1.21 billion, a PE ratio of -28.55 and a beta of -1.87. Structure Therapeutics Inc. has a 52 week low of $13.22 and a 52 week high of $57.59. The business's 50-day moving average price is $21.89 and its 200-day moving average price is $25.14.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). Equities analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.